$11.99 Million in Sales Expected for CareDx, Inc. (CDNA) This Quarter
Wall Street brokerages expect that CareDx, Inc. (NASDAQ:CDNA) will report $11.99 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for CareDx’s earnings. The highest sales estimate is $12.33 million and the lowest is $11.65 million. CareDx posted sales of $12.48 million during the same quarter last year, which suggests a negative year over year growth rate of 3.9%. The company is expected to report its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that CareDx will report full-year sales of $11.99 million for the current fiscal year. For the next year, analysts anticipate that the company will report sales of $56.06 million per share. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow CareDx.
CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, August 10th. The company reported ($0.19) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.19). The firm had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.87 million. CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%.
Several equities research analysts recently commented on the company. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a report on Monday, July 24th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a report on Thursday, August 24th.
Shares of CareDx (NASDAQ CDNA) traded up 8.79% during trading on Friday, hitting $2.97. The stock had a trading volume of 221,375 shares. The firm’s market cap is $66.95 million. The firm’s 50-day moving average is $2.18 and its 200 day moving average is $1.51. CareDx has a 52-week low of $0.76 and a 52-week high of $4.42.
In related news, major shareholder Neil Gagnon purchased 35,119 shares of the business’s stock in a transaction that occurred on Friday, August 25th. The stock was purchased at an average price of $2.92 per share, with a total value of $102,547.48. Following the completion of the acquisition, the insider now owns 890,473 shares in the company, valued at $2,600,181.16. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 130,802 shares of company stock valued at $257,457. Insiders own 5.40% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC acquired a new stake in shares of CareDx in the second quarter valued at approximately $212,000. Royce & Associates LP increased its holdings in shares of CareDx by 39.3% in the second quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock valued at $814,000 after purchasing an additional 206,815 shares during the last quarter. Finally, Gagnon Securities LLC increased its holdings in shares of CareDx by 2.9% in the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock valued at $2,314,000 after purchasing an additional 57,954 shares during the last quarter. 29.15% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “$11.99 Million in Sales Expected for CareDx, Inc. (CDNA) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/09/17/11-99-million-in-sales-expected-for-caredx-inc-cdna-this-quarter-2.html.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.